SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Fosaprepitant for Injection and ...

Geospatial Genomics: Operationalizing Multilevel Conceptual Frameworks of Cancer Health Outcomes to Account for Gene-Person-Place Relationships At the time of the primary PFS analysis, interim ...

Capivasertib, a potential first-in-class AKT inhibitor, combined with FASLODEX could become a new option for patients in this setting regardless of biomarker status WILMINGTON, Del.--(BUSINESS WIRE)-- ...

Avenacy, a specialty pharmaceutical company focused on supplying injectable medications, has launched Fosaprepitant for Injection and Fulvestrant Injection. “Avenacy has had a strong start to 2024, ...

CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining ...

VeraMorph Awarded an SBIR Fast Track Grant by NCI Towards Commercialization of the First Effective Oral Fulvestrant Therapy for ER+ Metastatic Breast Cancer Veramorph LLC (VeraMorph), a science-driven ...

A total of 62 patients were initially screened across five study centers for eligibility in this study. Of these, 15 patients were excluded due to various reasons: 10 failed the screening, 3 declined ...

Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926 Approval was based on CAPItello-291, a randomized, double-blind, ...

Veramorph LLC (VeraMorph), a science-driven startup developing a novel degradable gel as a solubility-enhancing oral drug delivery technology, has been awarded a Small Business Innovation Research ...